Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.46 |
| ▸ | FEN1 | P39748 | 4/20 | 0.46 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4227292 | 1.00 | USP30 (0.49) | USP30ALOX5APFEN1TRPV3HPGDS | |
| SCHEMBL4223141 | 0.87 | USP30 (0.53) | USP30TRPV3HDAC4HDAC6HSD11B1 | |
| SCHEMBL4223144 | 0.87 | USP30 (0.53) | USP30TRPV3HDAC4HDAC6HSD11B1 | |
| SCHEMBL4231271 | 0.87 | USP30 (0.53) | USP30TRPV3HDAC4HDAC6HSD11B1 | |
| SCHEMBL7881627 | 0.85 | HCRTR2 (0.44) | USP30 | |
| SCHEMBL4226729 | 0.85 | USP30 (0.56) | USP30TRPV3HPGDSHDAC4HDAC6 | |
| SCHEMBL4226723 | 0.85 | USP30 (0.56) | USP30TRPV3HPGDSHDAC4HDAC6 | |
| SCHEMBL4226480 | 0.83 | USP30 (0.49) | USP30ALOX5APFEN1TRPV3HPGDS | |
| SCHEMBL4237925 | 0.83 | GRM5 (0.57) | HSD11B1POLB | |
| SCHEMBL4237928 | 0.83 | GRM5 (0.57) | HSD11B1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | disclosed |
| EP-1893606-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006123255-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM3, GRM2 | USP30 1767/4885ALOX5AP 1088/4885FEN1 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.